


C. Mahony¹, G. Ouedraogo², P. Kukic³, M. Dent³, I. Willcox⁴, H. Wei⁴, F. Sadler⁴, A. Otto-Bruc⁴, A. Schepky⁵, M. Böttcher⁵, J. Ebmeyer⁵, D. Armstrong⁶, G. Kenna⁷, N.J. Hewitt⁸, M. Varcin⁸

¹ P&G, Procter & Gamble Technical Centres Ltd, Egham, UK; ² L'Oreal Life Sciences Research, Aulnay-Sous-Bois cedex, France; ³ Unilever, Safety & Environmental Assurance Centre, Sharnbrook, UK; ⁴ Eurofins Cerep S.A., at Le Bois L'Évêque, Celle L'Évescault, France; ⁵ Beiersdorf AG, R & D, Hamburg, Germany; ⁶ Duncan Armstrong, Armstrong Pharmacology Ltd., Macclesfield, UK; ⁷ Gerry Kenna Consulting, Macclesfield, UK ⁸ Cosmetics Europe, Brussels, Belgium

The Cosmetics Europe Systemic Toxicity Task Force has led the Pharmacology Profiling project, which aims to provide a screening approach using *in vitro* binding and enzymatic assays to identify and predict potential bioactivity of cosmetic-relevant chemicals. This approach is based on the knowledge that various targets of pharmacological interest have been linked to human adverse drug reactions (ADRs), and the screening of these has helped the pharma industry in identifying drug candidates, as well as off-target and potential adverse effects. In a feasibility study, a set of 100 cosmetically relevant chemicals will be profiled in the assays to develop a benchmark dataset. The aim of this work is to contribute to a practical, initial resource for Next Generation Risk Assessment (NGRA) to inform a possibly relevant systemic toxicity Mode of Action (MoA) of the cosmetic ingredient. Here, we describe the selection of chemicals and targets.



References:

Bowes et al., Nat Rev Drug Discov. 2012 Dec;11(12):909-22. doi: 10.1038/nrd3845; Cengiz M, Ozenirler S, Yilmaz G. Hepat Mon. 2014 Sep 24;14(9):e21885. doi: 10.5812/hepatmon.21885; Letswaart et al. EBioMedicine. 2020 Jul;57:102837. doi: 10.1016/j.ebiom.2020.102837; Lynch JJ 3rd et al., J Pharmacol Toxicol Methods. 2017 Sep;87:108-126. doi: 10.1016/j.vascn.2017.02.020; Mrema et al., Hum Exp Toxicol. 2013 Dec;32(12):1323-39. doi: 10.1177/0960327113485255; Iyer JK, Kalra M, Kaul A, Payton ME, Kaul R. Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol. 2017 Oct 7;23(37):6802-6816. doi: 10.3748/wjg.v23.i37.6802. PMID: 29085224; Pandey G, Pandey SP, Sharma M. Toxicol Int. 2011 Jul;18(2):160-2. doi: 10.4103/0971-6580.84270; Smit et al., Chem Res Toxicol. 2021 Feb 15;34(2):365-384. doi: 10.1021/acs.chemrestox.0c00294; Whitebread et al., Drug Discov Today. 2005 Nov 1;10(21):1421-33; Whitebread et al., Drug Discov Today. 2016 Aug;21(8):1232-42. doi: 10.1016/j.drudis.2016.04.021; Yamamoto et al., J Biol Chem. 2006 Jun 16;281(24):16625-31. doi: 10.1074/jbc.M602723200.